Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report

Prepared by Liverpool Reviews & Implementation Group, University of Liverpool.

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report
15 June 2012
(1.31 Mb 31 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 14 June 2012